The Cytokine Expression in Patients with Cardiac Complication after Immune Checkpoint Inhibitor Therapy
-
- Tsuruda Toshihiro
- Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Japan
-
- Yoshikawa Naoki
- Department of Pharmacy, University of Miyazaki Hospital, Japan
-
- Kai Motoaki
- Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Japan
-
- Yamaguchi Masashi
- Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Japan
-
- Toida Reiko
- Department of Cardiology, Chiyoda Hospital, Japan
-
- Kodama Tsuyoshi
- Department of Respiratory Medicine, Chiyoda Hospital, Japan
-
- Kajihara Kei
- Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine, University of Miyazaki, Japan
-
- Kawabata Takayuki
- Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine, University of Miyazaki, Japan
-
- Nakamura Takeshi
- Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine, University of Miyazaki, Japan
-
- Sakata Koji
- Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Japan
-
- Hatakeyama Kinta
- Department of Pathology, National Cerebral and Cardiovascular Center, Japan
-
- Gi Toshihiro
- Department of Pathology, Faculty of Medicine, University of Miyazaki, Japan
-
- Asada Yujiro
- Department of Pathology, Faculty of Medicine, University of Miyazaki, Japan
-
- Tono Tetsuya
- Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine, University of Miyazaki, Japan
-
- Kitamura Kazuo
- Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Japan
-
- Ikeda Ryuji
- Department of Pharmacy, University of Miyazaki Hospital, Japan
Search this article
Abstract
<p>We herein report the cytokine expression at different stages for three patients who developed cardiac complications after immune checkpoint inhibitor (ICI) therapy. Case 1 with biopsy-proven myocarditis showed increased levels of interleukin (IL)-8, monocyte chemotactic and activating factor, and granulocyte macrophage colony-stimulating factor (GM-CSF) when he developed Takotsubo cardiomyopathy. Case 2 with subclinical myocarditis showed predominant activation of IL-8 during the progressive clinical course. Case 3 with cytokine-releasing syndrome showed substantial activations of IL-6, IL-8, GM-CSF, and interferon-γ. Our data suggest the development of unique cytokine activation in individual patients with cardiac complications after ICI therapy. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 60 (3), 423-429, 2021-02-01
The Japanese Society of Internal Medicine